Objective: To observe the therapeutic effect of the TAC regimen combined with neoadjuvant endocrine therapy in HR-positive/HER-2-negative breast cancer. Methods: A total of 125 patients with HR-positive/HER-2-negative breast cancer from September 2020 to June 2024 were selected and divided into an observation group and a control group . The observation group was further divided into premenopausal and postmenopausal subgroups according to menstrual status. The control group received 6 cycles of ...更多
Objective: To observe the therapeutic effect of the TAC regimen combined with neoadjuvant endocrine therapy in HR-positive/HER-2-negative breast cancer. Methods: A total of 125 patients with HR-positive/HER-2-negative breast cancer from September 2020 to June 2024 were selected and divided into an observation group and a control group . The observation group was further divided into premenopausal and postmenopausal subgroups according to menstrual status. The control group received 6 cycles of TAC chemotherapy, and the observation group received endocrine therapy in addition to TAC chemotherapy. Surgery was performed after 6 cycles of neoadjuvant therapy. The MP grade, pathological complete response rate, objective response rate , change value of Ki-67, and incidence of adverse reactions were analyzed and compared between the observation group and the control group, within the observation groups, and between the observation group and the control group in different pathological stages. Results: There was no significant difference in the pCR rate between the observation group and the control group. The ORR of the observation group was higher than that of the control group , with a significant difference . The change value of Ki-67 in the observation group was greater than that in the control group , with a significant difference . The incidence of hot flashes in the observation group was higher than that in the control group. In the observation group, the objective response rate in Stage II was higher than that in Stage III , and the difference was statistically significant . The change value of Ki-67 in Stage II of the observation group was greater than that in Stage III , and the difference was statistically significant . There was no statistical difference in the remaining results. There was no difference in the results between premenopausal and postmenopausal patients within the observation group. Conclusion: Chemotherapy combined with neoadjuvant endocrine therapy can improve the ORR, improve the MP grade, and reduce Ki-67 in HR-positive/HER-2-negative breast cancer, with good safety.收起
发文期刊《Analysis of the Therapeutic Effect of TAC Regimen in Combination with Neoadjuvant Endocrine Therapy for HR-Positive/HER-2-Negative Breast Cancer》历年引证文献趋势图
